X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

New study finds some hospitals mark up medicine prices at least 700 percent

By Holly Campbell  |    September 5, 2018
A new analysis from The Moran Company found nearly one in five hospitals marks up medicine prices 700 percent or more. With this 700 percent markup, a $150 medicine purchased by a hospital could...   Read More

What they are saying: Study on cancer R&D costs is not an accurate representation of marketplace

By Holly Campbell  |    September 12, 2017
This post has been updated as of 10/2/2017 A recent study published in JAMA Internal Medicine provides flawed and inaccurate estimates of the significant research and development (R&D) investments...   Read More

340B Spotlight: 340B hospitals continue to benefit from consolidation at expense of patients

By Rebecca Davison  |    April 27, 2017
As we’ve noted before, incentives to profit under the 340B program are leading to an uneven playing field for providers and may be shifting care to more expensive and less convenient settings in...   Read More

340B Spotlight: Retail pharmacies continue to expand the 340B program

By Rebecca Davison  |    August 17, 2016
One area of needed reform in the 340B program is the use of contract pharmacy arrangements. A new analysis by Drug Channels  found more than one-in-four retail, mail and specialty pharmacies in...   Read More

340B Spotlight: New report raises questions about eligibility metric for 340B hospitals

By Karyn Schwartz  |    August 11, 2016
A new report from the Government Accountability Office (GAO) on how hospitals qualify for certain uncompensated care payments raises questions about how a similar eligibility metric is used to...   Read More

340B Spotlight: A look at 340B eligibility and charity care

By Allyson Funk  |    May 17, 2016
Last week the Alliance for Integrity and Reform of 340B (AIR340B)—of which PhRMA is a member—released a new report looking at charity care provided by 340B hospitals. This expands on previous...   Read More

340B Spotlight: Despite access to discounts, many 340B hospitals fail to comply with ACA charity care requirements

By Rebecca Davison  |    April 28, 2016
Late last year, we highlighted a study published in in the New England Journal of Medicine that found many nonprofit hospitals were not complying with the charity care requirements laid out in the   Read More

New report confirms competitive market works; Net prices for medicines increased just 2.8 percent in 2015

By Holly Campbell  |    April 14, 2016
Despite misleading claims made about spending on new innovative treatments and cures, another report confirms how the competitive biopharmaceutical market works to control costs. Net prices for...   Read More

New research: Insurance plan structure can have discriminatory effect

By Karyn Schwartz  |    March 31, 2016
New research from the Harvard University Center for Health Law and Policy Innovation (CHLPI) is another piece of evidence showing how health insurance plan design may be trying to discourage...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates